Sec Form 4 Filing - McInaw Michael @ Aevi Genomic Medicine, Inc. - 2020-02-03

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person McInaw Michael 2. Issuer Name and Ticker or Trading Symbol Aevi Genomic Medicine, Inc. [ GNMX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Interim CFO (Last) (First) (Middle) C/O AEVI GENOMIC MEDICINE, INC., 435 DEVON PARK DRIVE, SUITE 715 3. Date of Earliest Transaction (MM/DD/YY) 02/03/2020 (Street) WAYNE, PA19087 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 02/03/2020 D 16,107 D 16,107 D

D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Purchase) $ 5.77 02/03/2020 D 6,500 ( 2 ) 07/29/2026 Common Stock 6,500 $ 0 0 Stock Option (Right to Purchase) $ 4.91 02/03/2020 D 1,500 ( 3 ) 02/17/2027 Common Stock 1,500 $ 0 0 D Stock Option (Right to Purchase) $ 1.24 02/03/2020 D 5,000 ( 4 ) 06/02/2027 Common Stock 5,000 $ 0 0 D Stock Option (Right to Purchase) $ 1.32 02/03/2020 D 5,000 ( 5 ) 08/11/2027 Common Stock 5,000 $ 0 0 D Stock Option (Right to Purchase) $ 1.55 02/03/2020 D 26,250 ( 6 ) 04/17/2028 Common Stock 26,250 $ 0 0 D Stock Option (Right to Purchase) $ 1.52 02/03/2020 D 6,500 ( 7 ) 01/22/2028 Common Stock 6,500 $ 0 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other McInaw Michael C/O AEVI GENOMIC MEDICINE, INC. 435 DEVON PARK DRIVE, SUITE 715 WAYNE, PA19087 Interim CFO Signatures /s/ Michael McInaw 02/05/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Disposed of as a result of the merger pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger"). At the effective time of the Merger, holders of issuer common stock received (A) the fraction of a share of Cerecor common stock equal to the exchange ratio of 0.0334 (B) one contingent value right, which represents the right to receive contingent payments upon the achievement of certain milestones and (C) cash in lieu of any fractional shares of Cerecor common stock. ( 2 )This option, which became exercisable on July 29, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. ( 3 )This option, which became exercisable on February 17, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. ( 4 )This option, which became exercisable on June 2, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. ( 5 )This option, which became exercisable on August 11, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. ( 6 )This option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. ( 7 )This option, which became exercisable on March 30, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.